Crestor pharmacokinetics
Pro Research Analysisby 
Searched over 200M research papers for "Crestor pharmacokinetics"
Crestor Pharmacokinetics: Absorption, Bioavailability, and Metabolism
Crestor (rosuvastatin calcium) is a statin medication widely used to lower cholesterol. Its pharmacokinetics have been studied in various formulations and populations, providing a clear understanding of its absorption, bioavailability, and metabolism.
Absorption and Bioavailability of Crestor
Crestor is rapidly absorbed after oral administration. Studies in healthy volunteers show that the maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC) are consistent and predictable, with bioequivalence demonstrated between Crestor and several generic or combination formulations under fasting conditions. The 90% confidence intervals for Cmax and AUC fall within the accepted bioequivalence range (80%–125%), indicating that generic and fixed-dose combination products perform similarly to the original Crestor tablet in terms of absorption and overall exposure in the body Peña2024Khokhlov2022Seo2019+3 MORE.
Dissolution and In Vitro Performance
Crestor tablets show high drug release in various dissolution media, with over 88% of the drug released within 60 minutes in acidic conditions and nearly complete release in neutral or slightly basic buffers. This rapid and complete dissolution supports its reliable absorption in the gastrointestinal tract. Generic brands and fixed-dose combinations also meet pharmacopeial standards for dissolution, confirming their interchangeability with Crestor Alam2023Seo2019An2024.
Enhanced Formulations and Nanoparticle Delivery
Novel formulations, such as rosuvastatin calcium nanoparticles, have demonstrated significantly improved pharmacokinetic parameters. In animal studies, nanoparticle formulations increased oral bioavailability by 2.4 times compared to standard Crestor suspension, with a longer duration of lipid-lowering effects. This suggests that advanced delivery systems can further optimize rosuvastatin’s pharmacokinetic profile .
Metabolism and Tissue Selectivity
Crestor is characterized by minimal hepatic metabolism, with most of its biological activity attributed to the parent compound. It has a high affinity for the HMG-CoA reductase enzyme and is selectively taken up by liver cells, with little distribution to non-hepatic tissues. Importantly, rosuvastatin shows minimal interaction with the cytochrome P450 3A4 enzyme, reducing the risk of drug-drug interactions compared to other statins .
Pharmacokinetics in Combination Products
Fixed-dose combination tablets containing rosuvastatin (with drugs like losartan, amlodipine, clopidogrel, or dapagliflozin) have been shown to be bioequivalent to co-administered individual drugs. These combinations do not significantly alter the pharmacokinetic parameters of rosuvastatin, supporting their use for improved patient adherence without compromising efficacy or safety Khokhlov2022Seo2019An2024+1 MORE.
Conclusion
Crestor exhibits predictable and reliable pharmacokinetics, with rapid absorption, high bioavailability, and minimal metabolism. Its pharmacokinetic profile is maintained across generic, nanoparticle, and fixed-dose combination formulations, ensuring consistent therapeutic effects and supporting the interchangeability of these products in clinical practice Dudhipala2021Peña2024Khokhlov2022+5 MORE.
Sources and full results
Most relevant research papers on this topic